Biotechs target stagnant baldness market : Nature ...

Biotechs target stagnant baldness market. Charles Schmidt 1, Journal name: ... The deal gave Allergan rights to Kythera's oral PGD2 inhibitor, setipiprant, ...

Alexa Traffic


Listing Links